全文获取类型
收费全文 | 1208篇 |
免费 | 180篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 11篇 |
妇产科学 | 6篇 |
基础医学 | 29篇 |
口腔科学 | 16篇 |
临床医学 | 284篇 |
内科学 | 408篇 |
皮肤病学 | 16篇 |
神经病学 | 47篇 |
特种医学 | 5篇 |
外科学 | 69篇 |
综合类 | 64篇 |
预防医学 | 53篇 |
眼科学 | 3篇 |
药学 | 378篇 |
1篇 | |
中国医学 | 22篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 13篇 |
2022年 | 31篇 |
2021年 | 47篇 |
2020年 | 74篇 |
2019年 | 62篇 |
2018年 | 63篇 |
2017年 | 71篇 |
2016年 | 77篇 |
2015年 | 56篇 |
2014年 | 79篇 |
2013年 | 160篇 |
2012年 | 67篇 |
2011年 | 66篇 |
2010年 | 65篇 |
2009年 | 53篇 |
2008年 | 47篇 |
2007年 | 50篇 |
2006年 | 38篇 |
2005年 | 33篇 |
2004年 | 37篇 |
2003年 | 28篇 |
2002年 | 30篇 |
2001年 | 24篇 |
2000年 | 15篇 |
1999年 | 13篇 |
1998年 | 20篇 |
1997年 | 14篇 |
1996年 | 16篇 |
1995年 | 5篇 |
1994年 | 12篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 6篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 2篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1979年 | 2篇 |
1977年 | 3篇 |
1976年 | 1篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1973年 | 2篇 |
排序方式: 共有1429条查询结果,搜索用时 15 毫秒
1.
Yaqian Li Jingjing Yu Yun Kuang Chengkun Wu Liu Yang Qiulian Fang 《Current medical research and opinion》2020,36(9):1433-1439
Abstract
Objective
The sex, age, medical history, treatment, tobacco use, race risk (SAMe-TT2R2) Score; the sex, age, medical history, treatment, tobacco use, genotype combination (SAMe-TT2G2) Score; and the so-called modified SAMe-TT2R2 scores have been proposed to predict the anticoagulation quality for patients with non-valvular atrial fibrillation (NVAF). The data from a prospective controlled study is used to validate the SAMe-TT2R2 and SAMe-TT2G2 scores in Chinese NVAF patients treated with warfarin and to evaluate the association of factors with time in therapeutic range (TTR) to predict the quality of oral anticoagulation control. 相似文献2.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
3.
《The Journal of emergency medicine》2020,58(2):183-190
BackgroundIncidence of delayed intracranial hemorrhage (DICH) in patients on warfarin has been controversial. No previous literature has reported the utility of international normalized ratio (INR) in predicting traumatic DICH.ObjectivesUtilizing INR to risk stratify head trauma patients who may be managed without repeat imaging.MethodsThis was a retrospective study at a Level II trauma center. All patients on warfarin with head injuries from March 2014 to December 31, 2017 were included. Each patient underwent an initial head computed tomography scan (HCT) and subsequent repeat HCT 12 h after. Patients presenting > 12 h after head injury received only one HCT. Two blinded neuroradiologists reviewed each case of DICH. Statistical analysis evaluated Glasgow Coma Scale (GCS), Injury Severity Score (ISS), heart rate, systolic blood pressure (SBP), age, and platelet count.ResultsThere were 395 patients who qualified for the protocol; 238 were female. Average age was 79 years. Seventy-seven percent of patients underwent repeat HCT. Five resulted in DICH (INR 2.6–3.0), three of which might have been present on initial HCT; incidence rate of 0.51–1.27%. One patient required neurosurgical intervention. Among 80 patients with INR < 2, no DICH was identified, resulting in high sensitivity, but with a wide confidence interval; sensitivity of 100% (95% confidence interval [CI] 47.8–100), specificity 21% (95% CI 16.6–28.9). Correlation of factors: ISS (p = 0.039), GCS (p = 0.978), HR (p = 0.601), SBP (p = 0.198), age (p = 0.014), and platelets (p = 0.281).ConclusionNo patient with INR < 2 suffered DICH, suggesting that warfarin users presenting with INR < 2 may be managed without repeat HCT. For INR > 2, patients age and injury severity can be used for shared decision-making to discharge home with standard head injury precautions and no repeat HCT. 相似文献
4.
5.
M. J. Ray P. A. Carroll S. J. E. Just G. A. T. Hawson J. H. N. Belt 《Journal of clinical monitoring and computing》1994,10(2):97-100
Objective. The Ciba Corning 512 coagulation monitor (CC512) can be used to monitor heparin therapy by performing an activated
partial thromboplastin time (APTT) at the patient’s bedside. This study was designed to compare the CC512 results to results
using the laboratory system. The relative sensitivities of both systems to the effect of oral anticoagulant therapy also was
investigated.Methods. Activated partial thromboplastin times were performed with both the CC512 and laboratory system on 74 specimens from patients
receiving IV heparin therapy, and on 14 specimens from patients on warfarin only. Heparin assays were performed on 43 of the
specimens from the heparinized patients.Results. When a patient was receiving heparin only, the APTT results of the CC512 proved to be similar to existing laboratory methods.
The CC512 APTT results of patients on warfarin only were markedly prolonged, whereas the laboratory APTTs were only slightly
affected.Conclusion. The CC512 results were comparable to the laboratory system. However, the CC512 APTT was more sensitive to the effect of
warfarin than the laboratory APTT system used in this study. CC512 APTT results on a patient receiving both oral and intravenous
anticoagulation could be misleading.
The authors wish to thank D.M. O’Brien and the nursing staff of the Coronary Care Unit for providing CC512 data and laboratory
specimens, and I. Smith for the preparation of graphics. We also wish to thank Australian Diagnostics Corporation, which provided
consumables. 相似文献
6.
Chinese herbs and warfarin potentiation by 'Danshen' 总被引:4,自引:0,他引:4
CHEUK M. YU JULIANA C. N. CHAN & JOHN E. SANDERSON 《Journal of internal medicine》1997,241(4):337-339
Drug interactions with warfarin can be dangerous and although common drug interactions are now well recognized those with Chinese herbs are not widely appreciated. 'Danshen' is a herbal medicine often used for various complaints, particularly cardiovascular, in the Chinese community. We report a case of danshen-induced overcoagulation with severe and dangerous abnormalities of clotting in a patient with rheumatic heart disease. 相似文献
7.
Opong-Mensah K Woller TW Obaseki AO Porter WR 《Journal of pharmaceutical and biomedical analysis》1984,2(3-4):381-394
Equations have been developed that relate the concentration (or a parameter directly proportional to concentration, such as optical absorbance) of a weakly ionizable solute in a water-immiscible phase, in equilibrium with an aqueous phase, to the pH of the aqueous phase, the partition coefficient of the unionized solute and the phase volume ratio. These relationships have been used in the design of experimental methods for determining partition coefficients, which require measurement of solute concentration in only one phase. Data obtained in this way permit ready recognition of deviations from assumptions made in the development of the model; these assumptions include insolubility of the ionized solute in the water-immiscible phase and lack of interaction between buffer components and solute. Conditions for optimal liquid—liquid extraction of weakly ionizable solutes are more easily recognized. With these techniques, the negative logarithm of the acid dissociation constant (pK′a) and the logarithm of the octanol—water partition coefficient (log P) have been measured for warfarin (pK′a = 5.15 ± 0.04; log P = 2.82 ± 0.06), strychnine (pK′a = 8.29 ± 0.02; log P = 2.23 ± 0.04), phenol (pK′a = 9.88 ± 0.02; log P = 1.75 ± 0.05), procaine (pK′a = 8.11 ± 0.04; log P = 1.10 ± 0.08), and ephedrine (pK′a = 9.92 ± 0.01; log P = 1.65 ± 0.04) at 21°C. 相似文献
8.
Abdullah Saleh AlQattan MBBS Weaam Zohier Ghulam MBBS Najla Aldaoud MBBS Lama Algheryafi MBBS Nadia Aleisa MBBS Fozan A. Aldulaijan MBBS 《The breast journal》2021,27(3):258-263
Breast fat necrosis (BFN) is usually a benign inflammatory response to breast trauma. However, an extremely rare cause of fat necrosis is calciphylaxis, a calcification of small- and medium-sized arteries causing thrombosis and ischemia. It is classified into (A) uremic (B) nonuremic-induced calciphylaxis. Calciphylaxis has been reported to be encountered in different parts of the body. However, to the best of our knowledge there is only one case in the English literature of BFN 2ry to warfarin-induced calciphylaxis. We report a 65-year-old female, known case of atrial fibrillation on warfarin, presented with a left breast mass of 4-month duration. The mass was painful and progressively enlarging. Examination of the left breast showed 7 × 4 cm mass, spanning from 10-2 o'clock, free from surrounding structures, with preserved overlying skin. However, the mass was not visualized on mammogram. Ultrasound showed a left breast lobulated hypoechoic mass containing a hyperechoic component. Biopsy showed fat necrosis. After 1 month, she presented with ulceration of the overlying skin. After wide local excision, histopathology demonstrated a calciphylaxis-induced fat necrosis. Considering the patient's background, the diagnosis was BFN secondary to warfarin-induced calciphylaxis. Hence, the warfarin was shifted to Rivaroxaban, 6 months follow-up showed no evidence of recurrence. In conclusion, the rarity of nonuremic calciphylaxis is reflected on the delay of diagnosis in some of the reported cases and the lack of grading system used to guide the management of such difficult wounds. However, keeping a high index of suspicion is important whenever such wounds are encountered with presence of risk factors other than end-stage kidney disease. 相似文献
9.
低危非瓣膜病心房颤动患者抗栓疗效分析 总被引:1,自引:0,他引:1
目的:比较低危非瓣膜病心房颤动(AF)患者华法林和阿司匹林的疗效,以明确抗栓治疗的最佳策略。方法:资料来源于华法林(目标INR 2.0~3.0)与阿司匹林(150~160mg/d)的前瞻性随机对照研究,参考国际指南中关于非瓣膜病AF血栓栓塞高危因素的建议,低危分层标准为不具备任何一项高危因素:脑卒中病史、年龄大于75岁、糖尿病、心肌梗死、超声心动图EF小于40%。分析低危亚组中阿司匹林与华法林组血栓栓塞和出血事件。结果:低危亚组患者306例,平均年龄(61.9±9.3)岁,男性194例(63.4%),孤立性AF 41例(13.4%)。随访时间中位数19个月。服用阿司匹林患者发生血栓栓塞事件5例,华法林组仅1例,但统计学没有显著差异(P=0.219)。患者共发生出血事件11例,其中严重出血仅在华法林组有1例。华法林组总出血发生率高于阿司匹林组但没有统计学差异(P=0.288)。血栓栓塞和严重出血事件的联合终点[9例(5.6%)比3例(2.1%)P=0.146]两组间也没有差异。结论:不具有血栓栓塞高危因素的低危非瓣膜病AF患者,抗血小板药物阿司匹林与口服抗凝药物的疗效相似,但阿司匹林的剂量还需进一步研究。 相似文献
10.
目的 分析抗血小板及抗凝药物致消化道出血的危险因素及治疗策略。方法 临床药师参与1例消化道出血患者的治疗过程,从具体案例着手,结合患者病情进行系统分析。结果 双联抗血小板、华法林、未系统监测INR、高龄、未预防性使用质子泵抑制剂等引起患者慢性消化道出血加重,通过对症止血、补血处理及停用抗血小板及抗凝药物,患者出血症状得到有效控制。结论 对于消化道出血高危人群,应及时加用质子泵抑制剂至少3个月预防治疗。新型胃黏膜保护剂如瑞巴匹特等对抗血小板药物导致的消化道损伤亦有显著的预防作用,可考虑作为质子泵抑制剂的替代治疗。 相似文献